Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198


A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies.

Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S.

J Oncol Pharm Pract. 2018 Jan 1:1078155218783814. doi: 10.1177/1078155218783814. [Epub ahead of print]


Diabetes associated with immune checkpoint inhibition: presentation and management challenges.

Galligan A, Xu W, Fourlanos S, Nankervis A, Chiang C, Mant AM, Parente P, Rischin D, Krishnamurthy B, Sandhu S, Colman PG.

Diabet Med. 2018 Jun 16. doi: 10.1111/dme.13762. [Epub ahead of print]


PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1805131. [Epub ahead of print]


Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D.

J Clin Oncol. 2018 May 1;36(13):1275-1283. doi: 10.1200/JCO.2017.77.0941. Epub 2018 Mar 14.


Unilateral radiotherapy treatment for p16/human papillomavirus-positive squamous cell carcinoma of unknown primary in the head and neck.

Tiong A, Rischin D, Young RJ, Herschtal A, Solomon B, D'Costa I, Fua T, Liu C, Coleman A, Kleid S, Dixon BJ, Corry J.

Laryngoscope. 2018 Feb 26. doi: 10.1002/lary.27131. [Epub ahead of print]


Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03.

Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D.

J Med Imaging Radiat Oncol. 2018 Jun;62(3):412-419. doi: 10.1111/1754-9485.12705. Epub 2018 Feb 5.


High-Dose Cisplatin for Head and Neck Cancer Lives On.

Thai AA, Rischin D.

J Clin Oncol. 2018 Apr 10;36(11):1055-1057. doi: 10.1200/JCO.2017.76.8614. Epub 2018 Feb 2. No abstract available.


Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma.

Solomon B, Young RJ, Bressel M, Urban D, Hendry S, Thai A, Angel C, Haddad A, Kowanetz M, Fua T, Corry J, Fox S, Rischin D.

Cancer Immunol Res. 2018 Jan 29. doi: 10.1158/2326-6066.CIR-17-0299. [Epub ahead of print]


Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

Solomon B, Young RJ, Rischin D.

Semin Cancer Biol. 2018 Jan 30. pii: S1044-579X(17)30256-0. doi: 10.1016/j.semcancer.2018.01.008. [Epub ahead of print] Review.


The role of human papillomavirus in p16-positive oral cancers.

Belobrov S, Cornall AM, Young RJ, Koo K, Angel C, Wiesenfeld D, Rischin D, Garland SM, McCullough M.

J Oral Pathol Med. 2018 Jan;47(1):18-24. doi: 10.1111/jop.12649. Epub 2017 Oct 30.


Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG.

Le QT, Welch JJ, Vermorken JB, Rischin D, Mehanna H; all HNCIG investigators.

Oral Oncol. 2017 Aug;71:180-183. doi: 10.1016/j.oraloncology.2017.05.022. Epub 2017 Jun 22.


Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.

Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):948-954. doi: 10.1016/j.ijrobp.2017.02.088. Epub 2017 Feb 24.


Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation.

Kanjanapan Y, Deb S, Young RJ, Bressel M, Mileshkin L, Rischin D, Hofman MS, Narayan K, Siva S.

Clin Transl Radiat Oncol. 2017 Feb 8;2:53-58. doi: 10.1016/j.ctro.2017.01.003. eCollection 2017 Feb.


Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.


Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.


Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services.

Alexander M, Beattie-Manning R, Blum R, Byrne J, Hornby C, Kearny C, Love N, McGlashan J, McKiernan S, Milar JL, Murray D, Opat S, Parente P, Thomas J, Tweddle N, Underhill C, Whitfield K, Kirsa S, Rischin D.

Intern Med J. 2016 Aug;46(8):964-9. doi: 10.1111/imj.13157.


Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas.

Lim AM, Wong NC, Pidsley R, Zotenko E, Corry J, Dobrovic A, Clark SJ, Rischin D, Solomon B.

Clin Epigenetics. 2016 Jul 18;8:74. doi: 10.1186/s13148-016-0235-0. eCollection 2016.


Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

Banks PD, Sandhu S, Gyorki DE, Johnston ML, Rischin D.

J Oncol Pract. 2016 Jul;12(7):637-46. doi: 10.1200/JOP.2016.013367. Review.


Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Alexander M, Blum R, Burbury K, Coutsouvelis J, Dooley M, Fazil O, Griffiths T, Ismail H, Joshi S, Love N, Opat S, Parente P, Porter N, Ross E, Siderov J, Thomas P, White S, Kirsa S, Rischin D.

Intern Med J. 2017 Jan;47(1):16-34. doi: 10.1111/imj.13190. Review.


Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART).

Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Nuyts S, Wratten C, Rischin D.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):678-686. doi: 10.1016/j.ijrobp.2016.03.017. Epub 2016 Mar 23. Erratum in: Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):244.


BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B, Rischin D.

J Natl Compr Canc Netw. 2016 Mar;14(3):249-54. Epub 2016 Mar 8.


Individualised mindfulness-based stress reduction for head and neck cancer patients undergoing radiotherapy of curative intent: a descriptive pilot study.

Pollard A, Burchell JL, Castle D, Neilson K, Ftanou M, Corry J, Rischin D, Kissane DW, Krishnasamy M, Carlson LE, Couper J.

Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12474. Epub 2016 Mar 7.


p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high-risk human papillomavirus or prognosis and implications for the workup of the unknown primary.

McDowell LJ, Young RJ, Johnston ML, Tan TJ, Kleid S, Liu CS, Bressel M, Estall V, Rischin D, Solomon B, Corry J.

Cancer. 2016 Apr 15;122(8):1201-8. doi: 10.1002/cncr.29901. Epub 2016 Feb 16.


PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Rischin D, Spigel DR, Adkins D, Wein R, Arnold S, Singhal N, Lee O, Murugappan S.

Head Neck. 2016 Apr;38 Suppl 1:E1756-61. doi: 10.1002/hed.24311. Epub 2015 Dec 17.


Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.

Graves EE, Hicks RJ, Binns D, Bressel M, Le QT, Peters L, Young RJ, Rischin D.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):617-25. doi: 10.1007/s00259-015-3247-7. Epub 2015 Nov 18.


Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma.

Urban D, Corry J, Solomon B, Lim AM, Fua T, Coleman A, D'Costa I, Tiong A, Liu C, Peters LJ, Rischin D.

Head Neck. 2016 Apr;38 Suppl 1:E1117-21. doi: 10.1002/hed.24169. Epub 2015 Oct 13.


Overview of Advances in Head and Neck Cancer.

Rischin D, Ferris RL, Le QT.

J Clin Oncol. 2015 Oct 10;33(29):3225-6. doi: 10.1200/JCO.2015.63.6761. Epub 2015 Sep 8. Review. No abstract available.


Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG.

Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21.


¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.

Siva S, Deb S, Young RJ, Hicks RJ, Callahan J, Bressel M, Mileshkin L, Rischin D, Bernshaw D, Narayan K.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1825-32. doi: 10.1007/s00259-015-3112-8. Epub 2015 Jul 15.


Merkel cell carcinoma: emerging biology, current approaches, and future directions.

Tothill R, Estall V, Rischin D.

Am Soc Clin Oncol Educ Book. 2015:e519-26. doi: 10.14694/EdBook_AM.2015.35.e519. Review.


Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation.

Shah K, Te Marvelde L, Collins M, De Abreu Lourenco R, D'Costa I, Coleman A, Fua T, Liu C, Rischin D, Lau E, Corry J.

Oral Oncol. 2015 May;51(5):529-35. doi: 10.1016/j.oraloncology.2015.02.005. Epub 2015 Mar 6.


Abiraterone in metastatic salivary duct carcinoma.

Urban D, Rischin D, Angel C, D'Costa I, Solomon B.

J Natl Compr Canc Netw. 2015 Mar;13(3):288-90.


Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.

Young RJ, Urban D, Angel C, Corry J, Lyons B, Vallance N, Kleid S, Iseli TA, Solomon B, Rischin D.

Br J Cancer. 2015 Mar 17;112(6):1098-104. doi: 10.1038/bjc.2015.59.


Impact of center size and experience on outcomes in head and neck cancer.

Corry J, Peters LJ, Rischin D.

J Clin Oncol. 2015 Jan 10;33(2):138-40. doi: 10.1200/JCO.2014.58.2239. Epub 2014 Dec 8. No abstract available.


Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.

Lingaratnam SM, Slavin MA, Thursky KA, Teh BW, Haeusler GM, Seymour JF, Rischin D, Worth LJ.

Leuk Lymphoma. 2015 Jan;56(1):157-62. doi: 10.3109/10428194.2014.911861.


Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein.

Pendlebury A, Rischin D, Ireland-Jenkin K, Toner GC, Grant P.

J Clin Oncol. 2015 Aug 20;33(24):e99-100. doi: 10.1200/JCO.2013.49.8998. Epub 2014 Apr 7. No abstract available.


What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?

Urban D, Corry J, Rischin D.

Cancer. 2014 May 15;120(10):1462-70. doi: 10.1002/cncr.28595. Epub 2014 Feb 27. Review.


Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.

Trinkaus ME, Hicks RJ, Young RJ, Peters LJ, Solomon B, Bressel M, Corry J, Fisher R, Binns D, McArthur GA, Rischin D.

J Med Imaging Radiat Oncol. 2014 Feb;58(1):89-97. doi: 10.1111/1754-9485.12155.


Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.

Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, Solomon B.

Int J Cancer. 2014 Aug 15;135(4):887-95. doi: 10.1002/ijc.28727. Epub 2014 Jan 30.


Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome.

Lim AM, Candiloro IL, Wong N, Collins M, Do H, Takano EA, Angel C, Young RJ, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Rischin D, Solomon B, Dobrovic A.

Clin Epigenetics. 2014 Dec 9;6(1):22. doi: 10.1186/1868-7083-6-22. eCollection 2014.


T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy?

McDowell L, Collins M, Kleid S, Rischin D, Corry J.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Feb;117(2):163-9. doi: 10.1016/j.oooo.2013.09.005. Epub 2013 Nov 23.


Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD.

Clin Cancer Res. 2013 Nov 1;19(21):5960-71. doi: 10.1158/1078-0432.CCR-13-1337. Epub 2013 Sep 4.


Developing a performance data suite to facilitate lean improvement in a chemotherapy day unit.

Lingaratnam S, Murray D, Carle A, Kirsa SW, Paterson R, Rischin D.

J Oncol Pract. 2013 Jul;9(4):e115-21. doi: 10.1200/JOP.2012.000755. Epub 2013 Apr 9.


Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose.

Dooley MJ, Poole SG, Rischin D.

Ann Oncol. 2013 Nov;24(11):2746-52. doi: 10.1093/annonc/mdt300. Epub 2013 Aug 7.


Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.

Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, Roselt P, Eu P, Binns D, MacManus MP, Ball D, Hicks RJ.

J Med Imaging Radiat Oncol. 2013 Aug;57(4):475-81. doi: 10.1111/1754-9485.12086. Epub 2013 Jun 14.


Tonsillar cancer: the Peter MacCallum experience with unilateral and bilateral irradiation.

Liu C, Dutu G, Peters LJ, Rischin D, Corry J.

Head Neck. 2014 Mar;36(3):317-22. doi: 10.1002/hed.23297. Epub 2013 Jun 1.


Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.

Mak D, Hicks RJ, Rischin D, Solomon B, Peters L, Bressel M, Young RJ, Corry J.

J Med Imaging Radiat Oncol. 2013 Jun;57(3):364-72. doi: 10.1111/1754-9485.12024. Epub 2013 Jan 30.


Oral cyclophosphamide in recurrent ovarian cancer.

Handolias D, Quinn M, Foo S, Mileshkin L, Grant P, Dutu G, Rischin D.

Asia Pac J Clin Oncol. 2016 Mar;12(1):e154-60. doi: 10.1111/ajco.12074. Epub 2013 May 29.


Suboptimal health literacy in patients with lung cancer or head and neck cancer.

Koay K, Schofield P, Gough K, Buchbinder R, Rischin D, Ball D, Corry J, Osborne RH, Jefford M.

Support Care Cancer. 2013 Aug;21(8):2237-45. doi: 10.1007/s00520-013-1780-0. Epub 2013 Mar 19.


Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.

Young RJ, Lim AM, Angel C, Collins M, Deb S, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Russell PA, Wright G, McArthur GA, Fox SB, Rischin D, Solomon B.

Oral Oncol. 2013 Jun;49(6):576-81. doi: 10.1016/j.oraloncology.2013.01.006. Epub 2013 Feb 19.


Supplemental Content

Loading ...
Support Center